NASDAQ:XLO

Xilio Therapeutics - XLO Stock Forecast, Price & News

$3.65

-0.32 (-8.06%)

(As of 01/31/2023 12:00 AM ET)

Add

Compare

Today's Range: $3.50
▼
$4.07
50-Day Range: $1.97
▼
$4.28
52-Week Range: $1.95
▼
$14.86

Volume: 144,612 shs
Average Volume: 97,423 shs
Market Capitalization: $100.27 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.25

Institutional Ownership

Xilio Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 208.2% Upside
$11.25 Price Target
Short Interest: Healthy
0.19% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.66
Based on 9 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.12) to ($2.23) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

185th out of 1,055 stocks

Pharmaceutical Preparations Industry

86th out of 518 stocks

3.5

Analyst's Opinion

Consensus Rating
Xilio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.25, Xilio Therapeutics has a forecasted upside of 208.2% from its current price of $3.65.
Amount of Analyst Coverage
Xilio Therapeutics has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.19% of the float of Xilio Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Xilio Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Xilio Therapeutics has recently decreased by 31.43%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Xilio Therapeutics does not currently pay a dividend.
Dividend Growth
Xilio Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for XLO.

2.6

News and Social Media Coverage

News Sentiment
Xilio Therapeutics has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Xilio Therapeutics this week, compared to 0 articles on an average week.
Search Interest
1 people have searched for XLO on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Xilio Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.50% of the stock of Xilio Therapeutics is held by insiders.
Percentage Held by Institutions
60.46% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Xilio Therapeutics are expected to grow in the coming year, from ($3.12) to ($2.23) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Xilio Therapeutics is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Xilio Therapeutics is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Xilio Therapeutics has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Xilio Therapeutics (NASDAQ:XLO) Stock

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Receive XLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

XLO Stock News Headlines

January 28, 2023 | americanbankingnews.com

Xilio Therapeutics (NASDAQ:XLO) Price Target Cut to $10.00 by Analysts at Morgan Stanley

January 28, 2023 | americanbankingnews.com

Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Drop in Short Interest

January 31, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

January 26, 2023 | finance.yahoo.com

Institutions profited after Xilio Therapeutics, Inc.'s (NASDAQ:XLO) market cap rose US$33m last week butprivate equity firms profited the most

January 25, 2023 | seekingalpha.com

XLO Xilio Therapeutics, Inc.

January 25, 2023 | finance.yahoo.com

These 2 ‘Strong Buy’ Penny Stocks Are on Track for Massive Gains, Say Analysts

November 23, 2022 | finance.yahoo.com

Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12

November 9, 2022 | finance.yahoo.com

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results

January 31, 2023 | Porter & Company (Ad)

Is This The End of Capitalism?

EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…

September 23, 2022 | finance.yahoo.com

Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference

September 6, 2022 | finance.yahoo.com

Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

August 11, 2022 | seekingalpha.com

Xilio Therapeutics GAAP EPS of -$0.90

August 11, 2022 | finance.yahoo.com

Is Xilio Therapeutics (NASDAQ:XLO) In A Good Position To Invest In Growth?

August 9, 2022 | finance.yahoo.com

Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results

August 7, 2022 | finance.yahoo.com

Xilio Therapeutics, Inc. (XLO)

June 16, 2022 | finance.yahoo.com

Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President

May 18, 2022 | finance.yahoo.com

Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference

May 17, 2022 | finance.yahoo.com

Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer

May 12, 2022 | investing.com

Xilio Therapeutics Reports Pipeline and Business Highlights

May 12, 2022 | finance.yahoo.com

Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results

April 7, 2022 | finance.yahoo.com

Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

March 1, 2022 | seekingalpha.com

Xilio Therapeutics GAAP EPS of -$0.98 misses by $0.06

March 1, 2022 | finance.yahoo.com

Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

February 28, 2022 | finance.yahoo.com

Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference

February 7, 2022 | finance.yahoo.com

RiverVest Venture Management LLC Buys Xilio Therapeutics Inc

February 3, 2022 | finance.yahoo.com

Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day

January 25, 2022 | finance.yahoo.com

Are Institutions Heavily Invested In Xilio Therapeutics, Inc.'s (NASDAQ:XLO) Shares?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive XLO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

XLO Company Calendar

Last Earnings: 11/09/2022
Today: 1/31/2023
Next Earnings (Estimated): 3/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:XLO
CUSIP: N/A
CIK: 1840233
Web: www.xiliotx.com
Phone: 857-524-2466
Fax: N/A
Employees: 74
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.25
High Stock Price Forecast: $15.00
Low Stock Price Forecast: $7.00
Forecasted Upside/Downside: +208.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.38)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-75,800,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -54.95%
Return on Assets: -45.58%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 8.45
Quick Ratio: 8.45

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.95 per share
Price / Book: 0.53

Miscellaneous

Outstanding Shares: 27,470,000
Free Float: 26,510,000
Market Cap: $100.27 million
Optionable: Not Optionable
Beta: N/A

Key Executives

Dr. Rene Russo BCPS (Age 48)
Pharm.D, Pharm.D., CEO & Director
Comp: $873.8k

Dr. Martin H. Huber M.D. (Age 62)
Pres and Head of R&D
Comp: $739.46k

Mr. Edward C. English (Age 56)
VP of Fin. & Accounting, Treasury and Principal Accounting Officer

Dr. Uli Bialucha Ph.D.
Chief Scientific Officer

Mr. Christopher Frankenfield
Chief Legal & Admin. Officer

Julissa Viana
VP of Corp. Communications

Mr. Bill Avery Ph.D.
Sr. VP of Nonclinical Devel.

Ms. Stacey J. Davis
Chief Bus. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions

XLO Stock - Frequently Asked Questions

Should I buy or sell Xilio Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xilio Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XLO shares.
View XLO analyst ratings or view top-rated stocks.
What is Xilio Therapeutics' stock price forecast for 2023?: 3 brokerages have issued 12 month price objectives for Xilio Therapeutics' shares. Their XLO share price forecasts range from $7.00 to $15.00. On average, they expect the company's share price to reach $11.25 in the next year. This suggests a possible upside of 183.4% from the stock's current price.
View analysts price targets for XLO or view top-rated stocks among Wall Street analysts.
How have XLO shares performed in 2023?: Xilio Therapeutics' stock was trading at $2.69 on January 1st, 2023. Since then, XLO shares have increased by 47.6% and is now trading at $3.97.
View the best growth stocks for 2023 here.
Are investors shorting Xilio Therapeutics?: Xilio Therapeutics saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 19,200 shares, a decline of 31.4% from the December 31st total of 28,000 shares. Based on an average trading volume of 35,800 shares, the short-interest ratio is currently 0.5 days. Approximately 0.2% of the shares of the company are sold short.
View Xilio Therapeutics' Short Interest.
When is Xilio Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our XLO earnings forecast.

How were Xilio Therapeutics' earnings last quarter?: Xilio Therapeutics, Inc. (NASDAQ:XLO) released its earnings results on Wednesday, November, 9th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.17.
When did Xilio Therapeutics IPO?: (XLO) raised $125 million in an initial public offering (IPO) on Friday, October 22nd 2021. The company issued 7,353,000 shares at $16.00-$18.00 per share.
What is Xilio Therapeutics' stock symbol?: Xilio Therapeutics trades on the NASDAQ under the ticker symbol "XLO."
How do I buy shares of Xilio Therapeutics?: Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Xilio Therapeutics' stock price today?: One share of XLO stock can currently be purchased for approximately $3.97.
How much money does Xilio Therapeutics make?: Xilio Therapeutics (NASDAQ:XLO) has a market capitalization of $109.06 million. The company earns $-75,800,000.00 in net income (profit) each year or ($3.38) on an earnings per share basis.
How can I contact Xilio Therapeutics?: The official website for the company is www.xiliotx.com. The company can be reached via phone at 857-524-2466 or via email at monique@thrustsc.com.

This page (NASDAQ:XLO) was last updated on 1/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Xilio Therapeutics - XLO Stock Forecast, Price & News

Xilio Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Xilio Therapeutics (NASDAQ:XLO) Stock

XLO Stock News Headlines

XLO Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

XLO Stock - Frequently Asked Questions

Overall MarketRank^™